NZ729118A - Dioxolane analogues of uridine for the treatment of cancer - Google Patents
Dioxolane analogues of uridine for the treatment of cancerInfo
- Publication number
- NZ729118A NZ729118A NZ729118A NZ72911815A NZ729118A NZ 729118 A NZ729118 A NZ 729118A NZ 729118 A NZ729118 A NZ 729118A NZ 72911815 A NZ72911815 A NZ 72911815A NZ 729118 A NZ729118 A NZ 729118A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- treatment
- uridine
- c6alkyl
- dioxolane
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ762628A NZ762628A (en) | 2014-08-25 | 2015-08-24 | Dioxolane analogues of uridine for the treatment of cancer |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1450983 | 2014-08-25 | ||
| SE1550858 | 2015-06-22 | ||
| PCT/EP2015/069370 WO2016030335A1 (en) | 2014-08-25 | 2015-08-24 | Dioxolane analogues of uridine for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ729118A true NZ729118A (en) | 2022-02-25 |
Family
ID=54014804
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ729118A NZ729118A (en) | 2014-08-25 | 2015-08-24 | Dioxolane analogues of uridine for the treatment of cancer |
| NZ762628A NZ762628A (en) | 2014-08-25 | 2015-08-24 | Dioxolane analogues of uridine for the treatment of cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ762628A NZ762628A (en) | 2014-08-25 | 2015-08-24 | Dioxolane analogues of uridine for the treatment of cancer |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US10144750B2 (enExample) |
| EP (2) | EP3572410B1 (enExample) |
| JP (2) | JP6663424B2 (enExample) |
| KR (2) | KR102398714B1 (enExample) |
| CN (4) | CN110790789B (enExample) |
| AU (2) | AU2015308988C1 (enExample) |
| BR (1) | BR112017003898B1 (enExample) |
| CA (2) | CA2956251C (enExample) |
| CY (1) | CY1122945T1 (enExample) |
| DK (2) | DK3186244T3 (enExample) |
| EA (2) | EA031106B1 (enExample) |
| ES (2) | ES2927212T3 (enExample) |
| HR (1) | HRP20201023T1 (enExample) |
| HU (2) | HUE050705T2 (enExample) |
| IL (2) | IL250344B (enExample) |
| MX (1) | MX369649B (enExample) |
| MY (2) | MY188089A (enExample) |
| NZ (2) | NZ729118A (enExample) |
| PH (2) | PH12017500184B1 (enExample) |
| PL (2) | PL3572410T3 (enExample) |
| PT (2) | PT3186244T (enExample) |
| SG (3) | SG10202001117YA (enExample) |
| WO (1) | WO2016030335A1 (enExample) |
| ZA (1) | ZA201802864B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2927212T3 (es) * | 2014-08-25 | 2022-11-03 | Medivir Ab | Análogos de dioxano de uridina para el tratamiento de cáncer |
| CN106543220A (zh) * | 2015-09-16 | 2017-03-29 | 博瑞生物医药（苏州）股份有限公司 | 氨基磷酸酯化合物及其制备方法和晶体 |
| KR20180101370A (ko) * | 2015-12-11 | 2018-09-12 | 뉴카나 피엘씨 | 인산염 유도체 및 젬시타빈 전구약물 nuc-1031의 부분입체 이성질체 선별적 합성 |
| WO2017151044A1 (en) * | 2016-03-02 | 2017-09-08 | Medivir Ab | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
| CN106432328B (zh) * | 2016-09-14 | 2019-03-22 | 江苏福瑞生物医药有限公司 | 一种索非布韦中间体的制备方法 |
| JP2020500853A (ja) * | 2016-11-18 | 2020-01-16 | ネウロビベ プハルマセウトイカル エービー | ミトコンドリアのプロトンイオノフォアの肝臓プロドラッグ |
| GB201709471D0 (en) * | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| WO2019245444A1 (en) | 2018-06-21 | 2019-12-26 | Medivir Ab | Base-modified cytidine nucleotides for leukemia therapy |
| JP7337539B2 (ja) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| US12303521B2 (en) * | 2019-02-18 | 2025-05-20 | Medivir Ab | Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-PD1 or anti-PDL1 monoclonal antibody |
| CN110964057B (zh) * | 2019-12-25 | 2022-05-06 | 东南大学 | 一种利用微流体反应装置制备索非布韦中间体的方法 |
| CN113402546A (zh) * | 2020-03-17 | 2021-09-17 | 浙江四维医药科技有限公司 | 一种瑞德西韦磷酸中间体尾链动态动力学拆分方法 |
| EP4135849B1 (en) * | 2020-04-15 | 2025-03-19 | Medivir AB | Miv-818/lenvatinib combination therapy for liver cancer |
| CN113754692B (zh) * | 2020-06-03 | 2022-06-10 | 上海交通大学 | 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法 |
| CN114685558A (zh) * | 2020-12-28 | 2022-07-01 | 尚科生物医药（上海）有限公司 | 一种瑞德西韦中间体的制备方法 |
| CN114249764A (zh) * | 2021-11-10 | 2022-03-29 | 宁波大学 | 一种磷酰胺酯类前药的中间体及其制备方法与应用 |
| WO2025155547A1 (en) * | 2024-01-17 | 2025-07-24 | University Of Georgia Research Foundation, Inc. | An efficient synthesis of beta-l-5-[(e)-2-bromovinyl)-1-((2s,4s)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) uracil)] (l-bhdu) via chiral pure l-dioxolane |
| CN119240898A (zh) * | 2024-11-21 | 2025-01-03 | 中冶赛迪工程技术股份有限公司 | 适用于连续流污水处理的精准调酸系统 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
| US6022876A (en) | 1996-11-15 | 2000-02-08 | Yale University | L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections |
| AU1201502A (en) * | 2000-10-13 | 2002-04-22 | Shire Biochem Inc | Dioxolane analogs for improved inter-cellular delivery |
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| WO2007106450A2 (en) * | 2006-03-10 | 2007-09-20 | University Of Georgia Research Foundation, Inc. | Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy |
| CA2662147A1 (en) | 2006-09-01 | 2008-03-13 | University Of Georgia Research Foundation, Inc. | L-oddc prodrugs for cancer |
| PL216525B1 (pl) | 2006-10-17 | 2014-04-30 | Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk | 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów |
| US20130143835A1 (en) * | 2011-12-05 | 2013-06-06 | Medivir Ab | HCV Polymerase Inhibitors |
| KR20160099090A (ko) * | 2013-11-27 | 2016-08-19 | 아이데닉스 파마슈티칼스 엘엘씨 | 간암의 치료를 위한 뉴클레오티드 |
| ES2927212T3 (es) * | 2014-08-25 | 2022-11-03 | Medivir Ab | Análogos de dioxano de uridina para el tratamiento de cáncer |
-
2015
- 2015-08-24 ES ES19177824T patent/ES2927212T3/es active Active
- 2015-08-24 NZ NZ729118A patent/NZ729118A/en unknown
- 2015-08-24 HU HUE15756888A patent/HUE050705T2/hu unknown
- 2015-08-24 EA EA201790328A patent/EA031106B1/ru not_active IP Right Cessation
- 2015-08-24 PT PT157568882T patent/PT3186244T/pt unknown
- 2015-08-24 SG SG10202001117YA patent/SG10202001117YA/en unknown
- 2015-08-24 MY MYPI2017700615A patent/MY188089A/en unknown
- 2015-08-24 CN CN201911148331.9A patent/CN110790789B/zh active Active
- 2015-08-24 HR HRP20201023TT patent/HRP20201023T1/hr unknown
- 2015-08-24 SG SG11201701172SA patent/SG11201701172SA/en unknown
- 2015-08-24 PT PT191778240T patent/PT3572410T/pt unknown
- 2015-08-24 HU HUE19177824A patent/HUE059640T2/hu unknown
- 2015-08-24 WO PCT/EP2015/069370 patent/WO2016030335A1/en not_active Ceased
- 2015-08-24 ES ES15756888T patent/ES2796089T3/es active Active
- 2015-08-24 EP EP19177824.0A patent/EP3572410B1/en active Active
- 2015-08-24 KR KR1020207008682A patent/KR102398714B1/ko active Active
- 2015-08-24 BR BR112017003898-6A patent/BR112017003898B1/pt active IP Right Grant
- 2015-08-24 NZ NZ762628A patent/NZ762628A/en unknown
- 2015-08-24 JP JP2017511226A patent/JP6663424B2/ja active Active
- 2015-08-24 PL PL19177824.0T patent/PL3572410T3/pl unknown
- 2015-08-24 DK DK15756888.2T patent/DK3186244T3/da active
- 2015-08-24 MX MX2017002328A patent/MX369649B/es active IP Right Grant
- 2015-08-24 EP EP15756888.2A patent/EP3186244B1/en active Active
- 2015-08-24 SG SG10201911558UA patent/SG10201911558UA/en unknown
- 2015-08-24 PL PL15756888T patent/PL3186244T3/pl unknown
- 2015-08-24 US US15/506,692 patent/US10144750B2/en active Active
- 2015-08-24 DK DK19177824.0T patent/DK3572410T3/da active
- 2015-08-24 CN CN202010199579.4A patent/CN111269264A/zh active Pending
- 2015-08-24 EA EA201890648A patent/EA033300B1/ru not_active IP Right Cessation
- 2015-08-24 CA CA2956251A patent/CA2956251C/en active Active
- 2015-08-24 CN CN201911149251.5A patent/CN110804072B/zh active Active
- 2015-08-24 KR KR1020177008235A patent/KR102396905B1/ko active Active
- 2015-08-24 CN CN201580056640.7A patent/CN107074826B/zh active Active
- 2015-08-24 CA CA3128645A patent/CA3128645C/en active Active
- 2015-08-24 AU AU2015308988A patent/AU2015308988C1/en active Active
-
2017
- 2017-01-30 IL IL250344A patent/IL250344B/en active IP Right Grant
- 2017-01-31 PH PH12017500184A patent/PH12017500184B1/en unknown
- 2017-02-22 MY MYPI2021007010A patent/MY198325A/en unknown
-
2018
- 2018-03-20 AU AU2018201980A patent/AU2018201980B2/en active Active
- 2018-05-02 ZA ZA2018/02864A patent/ZA201802864B/en unknown
- 2018-12-03 US US16/208,083 patent/US10336780B2/en active Active
-
2019
- 2019-05-21 IL IL266766A patent/IL266766B/en active IP Right Grant
- 2019-07-01 US US16/459,165 patent/US10654877B2/en active Active
- 2019-08-19 PH PH12019501919A patent/PH12019501919A1/en unknown
-
2020
- 2020-02-14 JP JP2020023051A patent/JP6905609B2/ja active Active
- 2020-04-13 US US16/847,477 patent/US10822360B2/en active Active
- 2020-05-22 CY CY20201100469T patent/CY1122945T1/el unknown
- 2020-11-02 US US17/087,483 patent/US11447511B2/en active Active
-
2022
- 2022-09-19 US US17/948,050 patent/US20230117570A1/en not_active Abandoned
-
2023
- 2023-05-31 US US18/326,992 patent/US20230382931A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501919A1 (en) | Dioxolane analogues of uridine for the treatment of cancer | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| EA201791563A1 (ru) | Замещенные нуклеозидные производные, полезные в качестве агентов против рака | |
| PH12020500072A1 (en) | Heterocyclic inhibitors of atr kinase | |
| MX2018009773A (es) | Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4). | |
| CR20200362A (es) | CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395) | |
| EA201691857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
| MX2016012829A (es) | Inhibidores de biaril cinasa. | |
| PH12018500987A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| TN2019000211A1 (en) | Antitumoral compounds | |
| MX2017003930A (es) | Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank. | |
| EA201790082A1 (ru) | Ингибиторы лизин-специфической демитилазы-1 | |
| PH12018502497A1 (en) | Adenosine derivatives for use in the treatment of cancer | |
| MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| MX2016009663A (es) | Derivados de icariina. | |
| EA201691549A1 (ru) | Ариллактамные ингибиторы киназы | |
| MA39824A (fr) | Composés azole amido-substitués | |
| MX388409B (es) | Composiciones y metodos para tratar canceres. | |
| MX2019001979A (es) | Agonista de ppar? para el tratamiento de neoplasias hematicas. | |
| MX2019002017A (es) | Derivados de sofosbuvir para el tratamiento de la hepatitis c. | |
| WO2019040104A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES | |
| PH12017500492A1 (en) | Crystalline bace inhibitors | |
| MX369008B (es) | Un proceso mejorado para la preparación de exametazima. | |
| WO2014180882A3 (en) | Treatment of brain metastasis from cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 AUG 2023 BY CAMILLA WELLIN / CPA GLOBAL CLARIVATE Effective date: 20220723 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 AUG 2024 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20230724 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 AUG 2025 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20240726 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 AUG 2026 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20250725 |